scholarly journals Advancement of Pediatric Blood and Marrow Transplantation Research in North America: Priorities of the Pediatric Blood and Marrow Transplant Consortium

2010 ◽  
Vol 16 (9) ◽  
pp. 1212-1221 ◽  
Author(s):  
Michael A. Pulsipher ◽  
Edwin M. Horwitz ◽  
Ann E. Haight ◽  
Richard Kadota ◽  
Allen R. Chen ◽  
...  
Keyword(s):  
North America ◽  
Marrow Transplantation ◽  
Marrow Transplant ◽  
Blood And Marrow Transplantation ◽  
Blood And Marrow Transplant

scholarly journals Publication bias is present in blood and marrow transplantation: an analysis of abstracts at an international meeting

Blood ◽  
2011 ◽  
Vol 118 (25) ◽  
pp. 6698-6701 ◽  
Author(s):  
Kristjan Paulson ◽  
Mahwash Saeed ◽  
Jennifer Mills ◽  
Geoff D. E. Cuvelier ◽  
Rajat Kumar ◽  
...  
Keyword(s):  
Impact Factor ◽  
Publication Bias ◽  
Marrow Transplantation ◽  
Preliminary Evidence ◽  
Marrow Transplant ◽  
Blood And Marrow Transplantation ◽  
Blood And Marrow Transplant ◽  
Status Number ◽  
American Society ◽  
Positive Results

Abstract Publication bias is the preferential publication of research with positive results, and is a threat to the validity of medical literature. Preliminary evidence suggests that research in blood and marrow transplantation (BMT) lacks publication bias. We evaluated publication bias at an international conference, the 2006 Center for International Blood and Marrow Transplant Research (CIBMTR)/American Society for Blood and Marrow Transplantation (ASBMT) “tandem” meeting. All abstracts were categorized by type of research, funding status, number of centers, sample size, and direction of the results. Publication status was then determined for the abstracts by searching PubMed. Of 501 abstracts, 217 (43%) were later published as complete manuscripts. Abstracts with positive results were more likely to be published than those with negative or unstated results (P = .001). Furthermore, positive studies were published in journals with a mean impact factor of 6.92, whereas journals in which negative/unstated studies were published had an impact factor of only 4.30 (P = .02). We conclude that publication bias exists in the BMT literature. Full publication of research, regardless of direction of results, should be encouraged and the BMT community should be aware of the existence of publication bias.

Global Hematopoietic Stem Cell Transplantation (HSCT) At One Million: An Achievement Of Pioneers and Foreseeable Challenges For The Next Decade. A Report From The Worldwide Network For Blood and Marrow Transplantation (WBMT)

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2133-2133 ◽  
Author(s):  
Dietger Niederwieser ◽  
Marcelo C Pasquini ◽  
Mahmoud D. Aljurf ◽  
Dennis L. Confer ◽  
Helen Baldomero ◽  
...  
Keyword(s):  
Marrow Transplantation ◽  
Eastern Mediterranean ◽  
Marrow Transplant ◽  
Lymphoproliferative Disorders ◽  
Allogeneic Hsct ◽  
Blood And Marrow Transplantation ◽  
Blood And Marrow Transplant ◽  
The World ◽  
Unrelated Donors ◽  
Autologous Hsct

Abstract Since the first report by Nobel laureate, the late E. Donnall Thomas (NEJM, 1957, 257), HSCT has developed from an experimental to an established curative treatment for many congenital or acquired disorders of the hematopoietic system. The key steps of this success story are linked to progress in tissue typing, donor selection, supportive care and immunosuppression and fostered by intensive collaboration of physicians around the world through outcome and donor registries. The WBMT, a federation and official Non-governmental Organization of the World Health Organization, has collected HSCT activity data from its member societies and from national registries not part of an international HSCT society. Data collection did include the first transplants by ED Thomas and the first global report by M. Bortin (Transplantation 1970, 571). European data were derived from the Med A form of the European Group for Blood and Marrow Transplantation-EBMT for the years 1965-1989 and from the annual activity survey since 1990. Non-European data back to 1969 were provided by the Center for International Blood and Marrow Transplant Research-CIBMTR, with additional recent data provided by the Asia-Pacific Blood and Marrow Transplantation Group (APBMT, since 1974), the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR, since 1980), the Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT, since 1984), the Canadian Blood and Marrow Transplantation Group (CGBMT, since 2002), the Latin American Blood and Marrow Transplantation Group (LABMT, since 2009) and the African Blood and Marrow Transplant Group (AFBMT, since 2010). Double reporting was minimized by crosschecking registries and unrelated donations. Missing data from a few regions in 2012 were extrapolated from previous years assuming a 5% increase. As of December 2012, the 1450 transplant centers from 72 countries over 5 continents had reported 1.000.000 HSCT (58% autologous, 42% allogeneic). The dramatic recent increase in rate of utilization of HSCT is illustrated by the fact that there were 10.000 HSCTs worldwide by 1985, 50.000 by 1990, 100.000 by 1994, 500.000 by 2004 and 1.000.000 by December 2012. The absolute and relative contribution differed significantly with Europe providing 53%, the Americas 31%, Australasia 14% and Eastern-Mediterranean and Africa 2% to the total HSCT number (allogeneic HSCT: 45%, 32%, 20% and 3%; autologous HSCT: 58%, 31%, 10% and 1%). The increase in activity has been almost linear over the past 55 years with two exceptions, a decrease in autologous HSCT for breast cancer from 1999 especially in the Americas and a decrease in allogeneic HSCT for CML after 2000 seen everywhere except in the Eastern-Mediterranean/African region. The rise in HSCT numbers during the last decade was mainly due to an increase in allogeneic HSCT from unrelated donors; the relative increase being highest in Australasia. Recent growth was primarily due to increases in activity in existing transplant centers, rather than in the number of transplant centers. The main indications for autologous HSCT today are lymphoproliferative disorders 87% (myeloma 46% and lymphoma 41%), solid tumors 8.6% and AML 2.75%; for allogeneic HSCT leukemias 73% (AML 34.6%; ALL 16.8%; CML 4%; myelodysplastic and myeloproliferative disorders 13.3%; CLL 2.9% and other leukemias 1%), lymphoproliferative disorders 14.3% and bone marrow failure syndromes 5.5%. In 2010, cord blood was used as stem cell source in 19% of unrelated HSCT. These data were compiled through collaboration of the global HSCT community. Global collaboration has also been essential for the diffusion of HSCT as a therapy and especially for unrelated HSCT. More than 22 million unrelated donors are available today from a global network (World Marrow Donor Association, WMDA) of donor registries and cord blood banks and about 30% of unrelated HSCT involve a donor and recipient in different countries. The success of HSCT serves as a model for organ repair by the use of healthy stem cells and as a model for global cooperation in meeting the needs of an international patient population. These data also illustrate the challenges for the global medical community in providing state of the art care in regions with constrained resources and the need to find ways to make the therapy more available in order to provide better outcomes for patients with life-threatening but potentially curable diseases. Disclosures: Gluckman: Cord use: Honoraria; gamida: Honoraria.

scholarly journals How I vaccinate blood and marrow transplant recipients

Blood ◽  
2016 ◽  
Vol 127 (23) ◽  
pp. 2824-2832 ◽  
Author(s):  
Paul A. Carpenter ◽  
Janet A. Englund
Keyword(s):  
Marrow Transplantation ◽  
Good Clinical Practice ◽  
Marrow Transplant ◽  
The Body ◽  
Transplant Recipients ◽  
Blood And Marrow Transplantation ◽  
Blood And Marrow Transplant ◽  
Age Related ◽  
Clinical Scenarios ◽  
Adequate Data

Abstract Vaccination guidelines for recipients of blood and marrow transplantation (BMT) have been published by 3 major societies: American Blood and Marrow Transplantation, European Group of Blood and Marrow Transplantation, and Infectious Disease Society of America. Despite these extensive review articles, clinicians caring for BMT recipients continue to field frequently asked questions (FAQs) regarding the “who, when, and how” of feasible and effective posttransplant vaccination, frequently in the absence of adequate data. This may reflect discomfort with a “one size fits all” policy that makes no adjustments for different posttransplant clinical scenarios. Existing guidelines also lack practical dose clarifications when administering vaccines to patients who differ by age, underlying diagnosis, or amount of immunosuppressive therapy. Frequently, little or conflicting guidance is given regarding age-related schedules for certain vaccines (eg, meningococcal; tetanus toxoid, reduced diphtheria toxoid, and reduced acellular pertussis; and human papillomavirus vaccines) in addition to time posttransplant or other factors. FAQs and their answers form the body of this article and are shared with readers as a concise practical review, with the intent to facilitate good clinical practice.

Sign in / Sign up

Export Citation Format

Share Document